## Lulla PD. CAR T cells and autologous transplantation can coexist for DLBCL. *Blood*. 2021;139(9):1266-1267.

Page 1266: In the paragraph that begins with "Results from," the passage "In practice, however, we will still see patients who have received 1 to 2 cycles of salvage chemotherapy (not allowed in ZUMA7 or TRANSFORM) before consideration of a cell therapy, who do not fit the early chemotherapy failure criteria in those trials (ie, refractory to or relapsed within 12 months of first-line chemotherapy), or who cannot readily access a CAR T-cell center. Indeed, the EFS was not different between the standard of care and CAR T cells in the BELINDA trial, which had a design similar to those of ZUMA-7 and TRANSFORM except that it permitted salvage chemotherapy prior to administration of another potent CD19 CAR T-cell product, tisagenlecleucel.<sup>8</sup>" should read, "In practice, however, we will still see patients who have received salvage chemotherapy (not allowed in ZUMA7 and only 1 cycle in TRANSFORM, which is not typical salvage) before consideration of a cell therapy, who do not fit the early chemotherapy failure criteria in those trials (ie, refractory to or relapsed within 12 months of first-line chemotherapy), or who cannot readily access a CAR T-cell center. Indeed, the EFS was not different between the standard of care and CAR T cells in the BELINDA trial, which had a design similar to those of ZUMA-7 and only 1 cycle in TRANSFORM, which is not typical salvage) before consideration of a cell therapy, who do not fit the early chemotherapy failure criteria in those trials (ie, refractory to or relapsed within 12 months of first-line chemotherapy), or who cannot readily access a CAR T-cell center. Indeed, the EFS was not different between the standard of care and CAR T cells in the BELINDA trial, which had a design similar to those of ZUMA-7 and TRANSFORM except that it permitted standard salvage chemotherapy (~48% of patients received 2 or more salvage cycles) prior to administration of another potent CD19 CAR T-cell product, tisagenlecleucel.<sup>8</sup>" The errors have been corrected in the online version of the article.

**Errata** 

https://doi.org/10.1182/blood.2022017891

© 2022 by The American Society of Hematology

## Sangaletti S, Tripodo C, Chiodoni C, et al. Neutrophil extracellular traps mediate transfer of cytoplasmic neutrophil antigens to myeloid dendritic cells toward ANCA induction and associated autoimmunity. *Blood.* 2012;120(15):3007-3018.

Page 3011: In the left column of Figure 2C, the image for necrotic polymorphonuclear leukocytes (PMNs) stained with PKH-26 was inadvertently duplicated for apoptotic PMNs. In the legend to Figure 2, the sentence "Scale bars represent 5  $\mu$ m" should not appear in the description of panel A; the sentence "Scale bars represent 30  $\mu$ m" should not appear in the description of D and E, and the sentence "The scale bar represents 30  $\mu$ m" should be added to the description of panel F. The corrected Figure 2 and legend are shown below.